Clinical trials in Milówka

Researchers in Milówka are assessing the safety and tolerability of a new Pneumococcal vaccine for infants and adolescents.

• Safety profiling of the PG4 vaccine in healthy infants
• Evaluation of immune responses compared with adults aged 60+
• Assessment of vaccine tolerability in children and teens

All three trials are currently recruiting, providing participants with the chance to support vaccine safety monitoring.

Ongoing studies are investigating the safety and immunogenicity of RSVpreF in pediatric populations at high risk for severe RSV disease.

• Safety assessment in children with chronic medical conditions
• Immunogenicity testing in immunocompromised youths
• Non‑inferiority comparison of immune responses with older adults

The trials aim to demonstrate both a favorable safety profile and robust immune protection for vulnerable children.

The city hosts a focused portfolio of clinical research targeting bacterial and viral respiratory infections.

• Three actively recruiting vaccine studies
• Two research sites and one leading investigator
• Therapeutic emphasis on bacterial infections, mycoses, and respiratory tract diseases

This concentrated effort highlights Milówka’s role in advancing preventive therapies for key respiratory pathogens.